top of page

Find us on Social Media

  • Instagram
  • Facebook
  • LinkedIn
  • YouTube
  • TikTok

Now Offering Genetic Consultations 

Genetic Education

in the Field of

Leading

AAFP.jpg

# 1 in Healthcare Genetics

Company Description: The Progenext Group uses a variety of approaches to fulfill its mission. The first approach is by providing high quality continuing medical education (CME). The Progenext Group provides quality learning on a national scale to a large array of healthcare professionals. The content of the CME program includes a broad range of activities and special attention is given to how healthcare genetics impacts patient care.

 

The second approach is by translating complex scientific information in an easy-to-grasp format that can be understood by both clinicians and general consumers. This is accomplished by using an assortment of platforms including written reports and short educational videos.

 

The Progenext Group is able to utilize a multitude of methods to convey complex information to both the general consumer as well as healthcare clinicians.

Bridging the knowledge gap and making science relatable. 

Mission: The mission of The Progenext Group is to bridge the knowledge gap between bench science and clinical practice.

Vision: The Progenext Group’s vision is a world where translational science is better understood and implemented so that the quality of patient care can be improved.

The Importance of Translational Science and the Public

The recent pandemic has demonstrated the necessity to implement innovative scientific discoveries quickly and effectively into clinical practice. The aim of translational science is to translate bench and clinical science into health practices that increase overall public health. Traditionally, translational science has been described as “bench to bedside” with the goal being the implementation of bench science into routine clinical practice. More recently this goal has been broadened to include practices that effect the community at large.

History has also shown that the public at large lacks the basic scientific knowledge needed to understand scientific innovations, which in turn makes the public hesitant to embrace new technologies as seen with mRNA vaccines. Furthermore, without the proper awareness clinicians can also be tentative to encourage the use of said technologies. Translational science is the key to bridging the gap between new discoveries and public consumption.

 

The Progenext Group is dedicated to helping both clinicians and the general consumer increase their scientific knowledge for the overall improvement of public health.

New Publications

Next-generation sequencing for constitutional variants in the clinical laboratory, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG)

Catherine Rehder 1Lora J H Bean 2David Bick 3Elizabeth Chao 4Wendy Chung 5Soma Das 6Julianne O'Daniel 7Heidi Rehm 8 9Vandana Shashi 10Lisa M Vincent 11 12ACMG Laboratory Quality Assurance Committee

Abstract

Next-generation sequencing (NGS) technologies are now established in clinical laboratories as a primary testing modality in genomic medicine. These technologies have reduced the cost of large-scale sequencing by several orders of magnitude. It is now cost-effective to analyze an individual with disease-targeted gene panels, exome sequencing, or genome sequencing to assist in the diagnosis of a wide array of clinical scenarios. While clinical validation and use of NGS in many settings is established, there are continuing challenges as technologies and the associated informatics evolve. To assist clinical laboratories with the validation of NGS methods and platforms, the ongoing monitoring of NGS testing to ensure quality results, and the interpretation and reporting of variants found using these technologies, the American College of Medical Genetics and Genomics (ACMG) has developed the following technical standards.

Bioinformatics Methods in Medical Genetics and Genomics

Yuriy L Orlov 1 2 3Ancha V Baranova 4 5Tatiana V Tatarinova 6 7

Abstract

Medical genomics relies on next-gen sequencing methods to decipher underlying molecular mechanisms of gene expression. This special issue collects materials originally presented at the "Centenary of Human Population Genetics" Conference-2019, in Moscow. Here we present some recent developments in computational methods tested on actual medical genetics problems dissected through genomics, transcriptomics and proteomics data analysis, gene networks, protein-protein interactions and biomedical literature mining. We have selected materials based on systems biology approaches, database mining. These methods and algorithms were discussed at the Digital Medical Forum-2019, organized by I.M. Sechenov First Moscow State Medical University presenting bioinformatics approaches for the drug targets discovery in cancer, its computational support, and digitalization of medical research, as well as at "Systems Biology and Bioinformatics"-2019 (SBB-2019) Young Scientists School in Novosibirsk, Russia. Selected recent advancements discussed at these events in the medical genomics and genetics areas are based on novel bioinformatics tools.

Medical Tablet

What We Stand For

The Progenext Group desires to bridge the knowledge gap between scientists, doctors and the general public. Our intention is to make complex scientific information more digestible and easy to understand. 

The Importance of Genomics in Healthcare

It has been nearly two decades since the completion of the Human Genome Project, which marked the start of the in-depth exploration of human genomics.

Since that time, technology has exponentially increased our understanding of genomics and the role they play in normal physiology as well as in pathophysiology. Furthermore, genomics plays an ever-increasing part in

healthcare with genetic testing being common place for hereditary cancers and for genetic abnormalities in utero. However, genomics still remains widely underutilized amongst healthcare clinicians.

Clinicians and their patients remain skeptical when it comes to new technologies, especially those that involve genetics. The Progenext Group seeks to improve overall scientific knowledge to decrease that skepticism. 

A Closer Look
bottom of page